SINGAPORE, Sept. 10, 2025 — EUDA Health Holdings Limited (NASDAQ: EUDA), herein referred to as “EUDA” or the “Company,” a Singaporean non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, announced today that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has executed a Letter of Intent (the “LOI”) for the potential acquisition of GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology firm established in Singapore.
GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that transforms human blood cells into clinical-grade, therapeutically viable stem cells. These iPSCs possess the capacity to differentiate into nearly any cell type in the human body, thereby enabling applications in drug discovery, disease modeling, regenerative medicine, and future cell-based therapies. Significantly, iPSCs provide pluripotency without the ethical concerns typically associated with embryonic stem cells, positioning them as one of the most promising areas in biotechnology.
Planned Expansion into iPSC Solutions
Under the LOI, EUDA and GO POSB are investigating the establishment of an advanced iPSC laboratory and cultivation facility in Shenzhen, China. This facility would serve as a central hub for storing, expanding, and distributing iPSC solutions to hospitals, clinics, and research centers across China, pending necessary regulatory approvals. EUDA commits to providing funding for its construction, while the two companies will collaborate with Singapore’s Agency for Science, Technology and Research (A*STAR) to further iPSC research, conduct clinical trials, and streamline regulatory pathways for therapeutic uses.
This collaboration will position EUDA to supply B2B iPSC solutions to the broader healthcare ecosystem, including hospitals, regenerative clinics, and biotech developers. Beyond foundational therapeutic applications, the platform also opens future avenues for off-the-shelf iPSC-derived product lines customized for Asia’s wellness and aesthetics markets, such as iPSC-based hair revitalization and facial treatments. These initiatives are designed to directly enhance EUDA’s expanding portfolio of stem cell treatments and supplements, thereby strengthening the Company’s integrated strategy for longevity and regenerative health.
Regarding EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a prominent Singapore-based non-invasive healthcare provider in Asia, concentrating its operations in Singapore, Malaysia, and China. The Company aims to achieve market leadership in non-invasive and preventive healthcare, with a strategic focus on the rapidly expanding longevity sector. Our mission is to address the evolving healthcare requirements of over 1.8 billion individuals across the region, which is experiencing significant demographic shifts as more than 30% of its population ages rapidly. By offering innovative, accessible, and scientifically validated health solutions, EUDA is well-positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also operates a property management business based in Singapore.
Statements Regarding the Future
This document may include forward-looking statements concerning potential risks and uncertainties. These statements typically utilize predictive language, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose,” and variations of these terms or similar expressions (or their negative counterparts). These forward-looking statements are not guarantees of future performance, conditions, or results, and they encompass numerous known and unknown risks, uncertainties, assumptions, and other critical factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Readers should not place excessive reliance on forward-looking statements, which are valid only as of the date of this document’s publication. These forward-looking statements are based on information from EUDA and Go POSB, as well as other sources deemed reliable. The Company does not assume any obligation to update or revise any forward-looking statements, whether due to new information, future events, or otherwise, except as legally mandated.
For Inquiries:
Christensen Advisory
Linda Bergkamp
Telephone: +1-480-614-3004
Email:
